MCID: PDT015
MIFTS: 20

Pediatric Supratentorial Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Pediatric Supratentorial Ependymoma

MalaCards integrated aliases for Pediatric Supratentorial Ependymoma:

Name: Pediatric Supratentorial Ependymoma 12
Pediatric Supratentorial Ependymoblastoma 12
Childhood Supratentorial Ependymoma 69
Pediatric Cerebral Ependymoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7502
UMLS 69 C0278650

Summaries for Pediatric Supratentorial Ependymoma

MalaCards based summary : Pediatric Supratentorial Ependymoma, also known as pediatric supratentorial ependymoblastoma, is related to ependymoma, and has symptoms including headache, nausea and seizures. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and spinal cord.

Related Diseases for Pediatric Supratentorial Ependymoma

Diseases related to Pediatric Supratentorial Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 ependymoma 9.8

Symptoms & Phenotypes for Pediatric Supratentorial Ependymoma

UMLS symptoms related to Pediatric Supratentorial Ependymoma:


headache, nausea, seizures, vomiting

Drugs & Therapeutics for Pediatric Supratentorial Ependymoma

Drugs for Pediatric Supratentorial Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
8 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
14
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
15 Alkylating Agents Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
18 Antimitotic Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
20 Antirheumatic Agents Phase 3,Phase 2,Phase 1
21 Dermatologic Agents Phase 3,Phase 2,Phase 1
22 Etoposide phosphate Phase 3,Phase 2,Phase 1
23 Folic Acid Antagonists Phase 3,Phase 2
24 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
25 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Vitamin B Complex Phase 3,Phase 2
28 Antiemetics Phase 3,Phase 1
29 Autonomic Agents Phase 3,Phase 1
30 BB 1101 Phase 3,Phase 2,Phase 1
31 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
32 Emetics Phase 3
33 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 3,Phase 1
35 Folate Nutraceutical Phase 3,Phase 2
36 Vitamin B9 Nutraceutical Phase 3,Phase 2
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
39
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
40
Carmustine Approved Phase 2 154-93-8 2578
41
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
42
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
43
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
44
Tamoxifen Approved Phase 2 10540-29-1 2733526
45
Levoleucovorin Approved Phase 2 68538-85-2
46
Mechlorethamine Approved Phase 2,Phase 1 51-75-2 4033
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Procarbazine Approved Phase 2 671-16-9 4915
49
Cyproheptadine Approved Phase 2 129-03-3 2913
50
Histamine Approved, Investigational Phase 2 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 62)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 liposomal vincristine sulfate;carboplatin;cyclophosphamide;etoposide;cisplatin
4 Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy Active, not recruiting NCT00683319 Phase 3 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
5 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
6 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
8 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
9 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
10 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
11 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
12 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
13 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
14 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
15 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
16 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
17 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
18 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
19 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
20 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
21 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
22 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
23 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
24 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
25 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
26 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
27 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
28 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
29 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
30 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
31 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
32 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
33 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
34 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
35 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
36 DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Completed NCT00004212 Phase 1 exatecan mesylate
37 ABT-751 in Treating Young Patients With Refractory Solid Tumors Completed NCT00036959 Phase 1 ABT-751
38 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors Completed NCT00303940 Phase 1 carboplatin;talabostat mesylate;temozolomide
39 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride
40 Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas Completed NCT00002753 Phase 1
41 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
42 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
43 Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors Completed NCT00138216 Phase 1 irinotecan hydrochloride;temozolomide;vincristine sulfate
44 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
45 Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Completed NCT00049023 Phase 1
46 Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma Recruiting NCT03206021 Phase 1 5 Azacytidine
47 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
48 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
49 Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors Terminated NCT00112619 Phase 1 topotecan hydrochloride
50 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna

Search NIH Clinical Center for Pediatric Supratentorial Ependymoma

Genetic Tests for Pediatric Supratentorial Ependymoma

Anatomical Context for Pediatric Supratentorial Ependymoma

MalaCards organs/tissues related to Pediatric Supratentorial Ependymoma:

39
Brain, Bone, Spinal Cord, Bone Marrow, T Cells, Liver

Publications for Pediatric Supratentorial Ependymoma

Articles related to Pediatric Supratentorial Ependymoma:

id Title Authors Year
1
Pediatric supratentorial ependymomas show more frequent deletions on chromosome 9 than infratentorial ependymomas: a microsatellite analysis. ( 19446744 )
2009

Variations for Pediatric Supratentorial Ependymoma

Expression for Pediatric Supratentorial Ependymoma

Search GEO for disease gene expression data for Pediatric Supratentorial Ependymoma.

Pathways for Pediatric Supratentorial Ependymoma

GO Terms for Pediatric Supratentorial Ependymoma

Sources for Pediatric Supratentorial Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....